PATIENT ADVOCACY GROUPS URGE FOR GREATER VOICE AS HOUSE ENERGY AND COMMERCE COMMITTEE REVIEWS FDA BIOSIMILAR APPROVAL PROCESS

Among its provisions, the BPCIA calls for the creation of a regulatory pathway for new, safe and effective biosimilar drugs, adding choice and additional treatment options for best environmental advocacy groups. Patient safety must remain the paramount concern in the FDA’s

See More

OPED BY LARRY LAMOTTE: THE HILL: FDA MUST PUT PATIENTS FIRST IN BIOSIMILAR APPROVAL PROCESS

The House Committee on Energy and Commerce will hold an oversight hearing today, Feb. 4, on a new class of drugs, biosimilars, and the Food and Drug Administration’s (FDA) system for approving and monitoring them. A biosimilar is highly similar to, but not an exact copy of, a biologic. Biologic drugs are complex therapies made […]

See More